French Language Validation of the 5-minutes Montreal Cognitive Assessment (MoCA)
- Conditions
- Evaluations, Diagnostic SelfCognitive Symptom
- Interventions
- Diagnostic Test: Full version of the Montreal Cognitive AssessmentDiagnostic Test: 5 minutes version of the Montreal Cognitive Assessment
- Registration Number
- NCT03232697
- Lead Sponsor
- University Hospital, Lille
- Brief Summary
The aim of the study is to validate a french version of the 5 minutes version of the Montreal Cognitive Assessment as compared to the french full version of this test.
- Detailed Description
The Montreal Cognitive Assessment (MOCA) is a test used to detect cognitive impairments. This test is available in different languages including french. A short version (the 5 minutes MOCA) has also been validated through a phone call use that allows to develop some epidemiological approaches. Nevertheless, this short version has not been validated in french.
The main aim of the study is to validate the french translation of the short version of the MOCA as compared the the full french version of the test.
To validate the short version, several groups of subjects will be included : healthy subjects, Alzheimer disease patients, Parkinson or Huntington diseases patients as well as diabetic patients.
The inclusion of both healthy subjects and patients with different types of cognitive impairments will allow to validate the short version of the test.
All subjects and patients will first be submitted to the full version of the MOCA during a face to face procedure. Thirty to forty days later, they will be submitted to the short version of the test through a phone call performed by an independent rater.
Subgroups of healthy subjects and patients will also be used to determine the test-retest and inter-rater reliability of the short version of the MOCA.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 236
Healthy Volunteers
- Volunteers, BMI <26
- free from neurological, psychiatric, metabolic or cardiac pathologies;
- Absence of active metabolic or cardiac diseases, unstabilized under treatment
- Pregnant test negative
Patients
- Patients suffering from pathologies that may be accompanied by cognitive decline or dementia (Alzheimer's disease, Parkinson's and Huntington's disease, diabetes) that meet the usual diagnostic criteria for these diseases;
- Patients should not start treatment of a new therapeutic class under test
- Pregnant or nursing women.
- Illiterate subjects
- Presence of uncorrected visual or auditory disturbances
- "Alcohol use disorder" observed at the Mini International Neuropsychiatric Inventory (MINI);
- "Substance use disorder" observed at the MINI;
- Participation in a therapeutic trial or in an exclusion period from a previous clinical trial;
- Patient whose physical or mental condition does not allow them to pass the study tests;
- Persons under guardianship or under trusteeship;
- Recent cognitive assessment (less than 6 months) by the classic MoCA
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Diabetic patients Full version of the Montreal Cognitive Assessment Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment Parkinson and Huntington patients Full version of the Montreal Cognitive Assessment Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment Alzheimer patients 5 minutes version of the Montreal Cognitive Assessment Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment Healthy subjects 5 minutes version of the Montreal Cognitive Assessment Subjects will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment Diabetic patients 5 minutes version of the Montreal Cognitive Assessment Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment Healthy subjects Full version of the Montreal Cognitive Assessment Subjects will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment Alzheimer patients Full version of the Montreal Cognitive Assessment Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment Parkinson and Huntington patients 5 minutes version of the Montreal Cognitive Assessment Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
- Primary Outcome Measures
Name Time Method Correlation between scores obtained with the different versions of the MOCA 30 to 40 days To measure the correlation between the results obtained at the short and full versions of the MOCA
- Secondary Outcome Measures
Name Time Method Performance of the short version of the MOCA 30 to 40 days Receiver operator characteristic (ROC) analyses of the short version of MOCA to determine cognitive impairment as compared to full version as a gold-standard
Test-retest reliability 30 to 40 days To determine the test-retest reliability of the short version of the MOCA
Inter-rater reliability 30 to 40 days To determine the inter-rater reliability of the short version of the MOCA
Trial Locations
- Locations (1)
University Hospital
🇫🇷Lille, France